Introduction

Neuroblastoma (NB) is almost exclusively a pediatric neoplasm and the most common extracranial solid tumor in children, accounting for 8-10% of all childhood cancers.\(^1\) It is the most common cancer diagnosed during infancy. Majority of children (62-70%) have metastatic disease at the time of presentation.\(^1,2\)

ABSTRACT

Background: To evaluate the role of positron emission tomography-computed tomography (PET-CT) in staging and determining early treatment response to chemotherapy in children with neuroblastoma (NB) and its correlation with the final outcome. Patients and Methods: Seventeen patients of NB with mean age of 51.5 months (age range 2-132 months; 14 males, 3 females) underwent serial 18F-fluorodeoxyglucose (FDG) PET-CT imaging. All 17 patients were for staging before any treatment. Twelve of 17 patients underwent I-131 meta-iodobezylguanidine (MIBG) scan and bone scan. MIBG uptake was seen in the primary lesion in 11/12 patients. MIBG uptake in bones was seen in 3/12 patients. All bone lesions were concordant on MIBG and bone scan. Early response to chemotherapy was evaluated after two cycles using PET-CT. A 30% reduction in longest diameter was taken as cut-off value for response on CT based on the response evaluation criteria in solid tumors criteria. Response on PET-CT was assessed using percentage improvement in lesion to background SUV ratio, taking a value of 50% as cut-off. Final outcome based on follow-up ranging from 6 to 43 months (mean 18.8 months) served as reference. Results: All 17 patients showed increased FDG uptake at the primary site. Seven of the 17 patients (41.2%) showed metastasis. Lymph nodes were the most common site of metastatic disease followed by bone, bone marrow, lung and meninges. For response evaluation, change in the size of the primary tumor was noted in 11/17 (64.7%) patients on CT. Treatment response was noted in 12/17 patients (70.6%) on PET-CT. Eleven out of 17 (65%) patients showed response in both CT and PET-CT. Five out of 17 patients showed no response in both. Discordant findings on CT and PET were noted in one (5.9%) patient where PET showed response but no response was seen on CT. Two patients with initial response but with distant metastases expired during follow-up. Conclusion: PET-CT has potential in the initial staging of NB. PET-CT also appears to be a good modality for response assessment in patients with moderate and high FDG uptake on the baseline scan. However, no significant beneficial effect was seen in patients with low baseline FDG uptake.

Keywords: Neuroblastoma, neoadjuvant chemotherapy, PET-CT, staging, treatment response evaluation

Address for correspondence:
Dr. Rakesh Kumar, E-81, Ansari Nagar (East), AIIMS Campus, New Delhi-110 029, India. E-mail: rkphulia@yahoo.com

Indian Journal of Nuclear Medicine | Vol. 25: Issue 4 | October-December, 2010

147
PATIENTS AND METHODS

Patients

The study was performed according to the approved guidelines of the institutional ethical committee. Informed written consent was taken from parents of all patients before the study. A total of 17 patients of histologically confirmed new cases of NB with no prior treatment were prospectively included in the study. Patients in whom the tumor was amenable to upfront surgical resection, patients with poor general condition, patients who could not be sedated and patients where the parents refused to give consent were excluded from the study. There were 14 male and 3 female patients; age range 2-132 months (mean 51.5 months) [Table 1].

All patients were investigated as per revised international criteria for NB diagnosis, staging and response to treatment.24 Twenty-four hour urinary catecholamines were used as tumor markers. Histological diagnosis was done by trucut biopsy or fine needle aspiration cytology. Contrast enhanced CT/MRI were used to determine the local extent of disease. Potential hematogenous and lymphatic metastatic sites were evaluated by CECT scan of the abdomen and chest or MRI, bone scan and bone marrow aspiration. Baseline evaluation was performed within 2 weeks preceding the start of treatment. In all patients, the same method of assessment was used to characterize the lesion at baseline and during follow-up. Patients were staged according to International NB Staging System (INSS).24 A baseline whole body PET-CT scan was performed. Following the baseline scan, stage 1, 2A, 4s patients underwent two cycles of chemotherapy with cyclophosphamide and adriamycin. Cisplatinum and etoposide were additionally used in patients with stage 2B, 3, 4 disease. A second PET-CT scan was performed after two cycles of chemotherapy.

PET-CT procedure

After fasting for at least 4 hrs and with patients in a resting state, in a quiet room, a dose of 5.3 MBq/kg (0.14 mCi/kg) of 18F-flourodeoxyglucose (FDG) was injected intravenously. Older children were instructed to lie still whereas smaller children were encouraged to sleep. Sedation was done when needed using 0.1 mg/kg midazolam to avoid motion artifacts. PET-CT scan was acquired on a dedicated PET-CT scanner approximately 60 mins after intravenous injection of radiotracer. CT scan acquisition was performed on spiral dual slice CT with a slice thickness of 4 mm and a pitch of 1. Image was acquired using a matrix of 512×512 pixels and pixel size of about 1 mm. After the transmission scan, 3D PET acquisition was taken for 3-5 mins per bed position for one-two bed position. PET data was acquired using matrix of 128×128 pixels with a slice thickness of 1.5 mm. CT-based attenuation correction of the emission images were employed. PET images were reconstructed by iterative method ordered subset expectation maximization (two iterations and eight subsets) with a filter of 5 mm. The CT images were acquired and reconstructed using optimized parameters for attenuation correction. Data obtained from the CT acquisition was used for low noise attenuation correction of PET emission data and for fusion of attenuation corrected PET images with the corresponding CT images. After completion of PET acquisition, the reconstructed attenuation –corrected PET images, CT images and fused images of matching pairs of PET and CT images were reviewed in axial, coronal and sagittal planes and in maximum intensity projections, three-dimensional cine mode. PET images were assessed to identify areas of increased radiotracer uptake. Corresponding areas in the CT images and fused PET-CT images were corroborated.

Data interpretation

Baseline FDG PET-CT study was performed for staging. Repeat PET-CT was done after two courses of NACT to evaluate

| Table 1: Patient characteristics |
|-------------------|---|
| Characteristics       | Values |
| Number of patients enrolled | 17 |
| Age (in months)       | 51.5 |
| Sex                   | 2-132 |
| Male                  | 14 |
| Female                | 3 |
| Total number of primary lesions | 17 |
| Site of lesions       | |
| Suprarenal            | 11 |
| Paraspinal            | 5 |
| Cervical              | 1 |
| Stage                 | |
| INSS-3                | 10 |
| INSS-4                | 7 |
treatment response. The PET-CT response was correlated with histopathology and clinical improvement. Histopathology was available in nine patients and remaining eight patients were evaluated based on clinical follow-up of minimum 6 months.

Qualitative criteria: FDG uptake in the lesion was compared with FDG uptake in normal liver parenchyma. Lesions were characterized as showing intense, moderate and mild FDG uptake when FDG uptake in tumor was significantly, moderately and slightly high, respectively, when compared with normal liver parenchyma. When uptake in lesion was equal or less in comparison with normal liver parenchyma then it was labeled as no FDG uptake. Where the liver had diffuse metastasis with no normal liver parenchyma visible on conventional imaging, normal splenic parenchyma was used as a comparison parameter.

Quantitative criteria: Standardized uptake value (SUV) in pediatric patients is not routinely being used in our institute. We, therefore, employed a method wherein we used the lesion to background (liver) ratio in the baseline as well as the scan done post two cycles of NACT. Comparison was made between the baseline scan and scan done post two cycles of NACT and the percentage improvement in the lesion to background SUV was calculated for all patients. As with other tumors, a 50% change in lesion to background ratio was taken as the cut-off value to classify as response.[11] In case of CT, RECIST criteria were used.[10]

RESULTS

PET-CT in staging

Out of the 17 patients, all 17 had undergone CECT to define the primary tumor and delineate the local extent of the disease. Primary tumor was seen in all patients on CECT (suprarenal 11, paraspinal 5, cervical 1). The size of the tumor ranged from 2.4 to 16.3 cm. Regional lymph nodes involvement were seen in 7/17 patients. A total of 69 lymph nodes were identified in seven patients. No other distant lesions were seen as the CT scan was limited to the primary site of disease.

Twelve of 17 patients underwent MIBG scan and bone scan (5/12 stage IV, 7/12 stage III). The remaining five patients could not undergo MIBG and bone scan due to technical limitations. MIBG uptake was seen in the primary lesion in 11/12 patients. The twelfth patient did not show any uptake. No lymph node could be identified distinct from the primary tumor in any of 12 patients who had MIBG scan. MIBG uptake in bones was seen in 3/12 patients. A total of 12 skeletal lesions were seen on MIBG scan. Bone can showed skeletal metastasis in 3/12 patients. A total of 12 skeletal lesions were identified on bone scan. All bone lesions were concordant on MIBG and bone scan.

Baseline PET-CT showed increased FDG uptake in the primary lesion in all 17 patients. Intense uptake was noted in seven patients, moderate in four patients and mild in six patients. The size of the primary tumor on the baseline CT ranged from 2.9 to 16.6 cm (mean 7.3 cm) [Table 2]. The lesion to background SUVmax ratio in the baseline PET-CT ranged from 0.8 to 7.0 cm (mean 3.5 cm) [Table 2]. Lymph node metastasis was seen in 7/17 patients. Regional lymph nodes could not be counted due to the high uptake in the primary tumor. Nineteen lymph nodes other than the regional lymph nodes were identified. Enlarged cervical lymph nodes with increased FDG uptake were seen in one patient (other than those mentioned above) with suprarenal NB which on biopsy came out as benign. PET-CT detected metastasis to the bone marrow and lung in two patients and meningeal metastasis in 1 patient [Figures 1 and 2]. Four additional skeletal lesions were seen apart from those seen on MIBG and bone scan.

| Table 2: Results |
|--------------------|
| Age (months) | Sex | Stage | Size on ct | SUV lesion to background ratio | Response | Period of follow-up (months) | Current disease status |
|--------------------|
| | | | | Baseline | Post two cycles chemother-apy | % change | Baseline | Post two cycles chemother-apy | % improvement | |
| | | | | | | | | | | |
| 72 | M | 6 | 4.5 | 6 | 3.6 | 45 | 7.0 | 1.5 | 79 | + + | CR | 9 | Died |
| 108 | M | 3 | 4.8 | 4.8 | - | - | 1.2 | 1.2 | - | - | - | PR | 29 | DF |
| 20 | M | 4 | 10.6 | 5.8 | 45 | 6.0 | 1.2 | 80 | + + | PR | 26 | Died |
| 2 | M | 3 | 7.8 | 7.1 | 9 | 1.3 | 1.2 | 8 | - | - | CR | 43 | Died |
| 36 | M | 3 | 10.8 | 10.1 | 11 | 6.8 | 1.1 | 84 | - | - | CR | 23 | DF |
| 72 | M | 4 | 6.7 | 3.0 | 55 | 5.0 | 1.5 | 70 | + + | PR | 25 | DF |
| 18 | F | 3 | 2.9 | - | 100 | 1.5 | - | 100 | + + | PR | 32 | DF |
| 108 | M | 3 | 16.6 | 14.1 | 15 | 0.8 | 0.8 | - | - | - | PR | 18 | DF |
| 132 | M | 3 | 12.6 | 8.4 | 33 | 1.6 | 0.2 | 88 | + + | CR | 14 | DF |
| 2 | M | 3 | 4.2 | 3.5 | 17 | 1.8 | 1.0 | 45 | - | - | CR | 14 | DF |
| 6 | F | 3 | 3.4 | 1.6 | 53 | 4.0 | 1.7 | 58 | + + | PR | 35 | DF |
| 72 | M | 4 | 11.0 | 6.8 | 48 | 2.6 | 1.6 | 61 | + + | PR | 13 | DF |
| 24 | F | 4 | 10.3 | 10.2 | 1 | 4.2 | 6.0 | - | - | - | PR | 10 | DF |
| 48 | M | 3 | 4.5 | - | 100 | 3.2 | - | 100 | + + | CR | 8 | DF |
| 120 | M | 4 | 6.0 | 3.2 | 47 | 5.4 | 2.1 | 61 | + + | PR | 8 | DF |
| 24 | M | 4 | 10.8 | - | 100 | 4.6 | - | 100 | + + | PR | 7 | DF |
| 12 | M | 3 | 4.5 | - | 100 | 2.4 | - | 100 | + + | CR | 6 | DF |
Figure 1: CT, PET, PET-CT and maximum intensity projection images (Left-Right) showing the presence of extensive disease in the abdomen and diffuse marrow metastasis.

Figure 2: CT, PET and PET-CT images (L-R) showing the right suprarenal mass occupying right side of abdomen, pushing the liver superiorly and diffuse marrow metastasis (upper row). Transaxial CT, PET and PET-CT images in the same patient showing the presence of lung metastasis (lower row).
Comparative results of various modalities used for staging
The primary tumor was well-delineated in all patients on CECT and PET-CT. MIBG scan was performed in 12 patients. MIBG uptake was seen in 11/12 patients.

Regional lymph nodes were best identified on CECT scan. Owing to high radiotracer uptake in PET scan and MIBG scan, and also the lack of anatomical markers on MIBG scan, regional lymph nodes could not be identified separately from the primary tumor.

Distant metastasis could not be picked up on the baseline CECT scan as the CECT scan was limited to the site of the primary lesion. Bone scan could identify skeletal metastasis in 3/12 patients. MIBG scan showed skeletal metastasis at the same sites which were seen on bone scan. No additional sites of metastasis were seen. PET-CT detected additional bone marrow, lung and meningeal metastases, in addition to four more skeletal lesions.

PET-CT in response evaluation
Response evaluation was done using PET-CT scan alone as all patients showed FDG uptake in the baseline PET-CT. No follow-up CECT, MIBG or bone scan was done for response evaluation. Non-contrast CT of PET-CT was used to measure the size of lesion whenever present to see the treatment response as per RECIST criteria.

Follow-up scan (After two cycles of NACT)
The size of the primary tumor on the follow-up CT ranged from no mass to 14.1 cm (mean 5.7 cm) [Table 2]. The lesion to background SUVmax in the follow-up PET ranged from no uptake (as mass was completely resolved) to 6.0 (mean 1.2) [Table 2]. Reduction in the size of the primary lesion was seen in 11/17 patients. No change was seen in 6/17 patients. Reduction in the lesion to background SUVmax of the primary lesion was seen in 12/17 patients. No change was seen in 5/17 patients.

Complete resolution (CR) of lymph nodes and marrow metastasis were seen in 2/7 patients and of bone metastasis in one patient. CR of FDG uptake was also seen in the meningeal metastasis. Partial response (PR) was seen in the other lesions.

Response analysis
As the number of patients in the study was small, the patients were grouped into responders and non-responders for analysis purpose. Responders comprised of those with CR and PR. The patients with stable disease and progression of disease were classified as non-responders.

Eleven out of 17 (65%) patients showed response in both CT and PET-CT [Figure 3]. Five out of 17 patients showed no response in both [Figure 4]. Discordant findings on CT and PET were noted in one (5.9%) patient where PET showed response but no response was seen on CT [Figure 5]. Two patients with initial response but with distant metastases expired during follow-up [Figure 6].

A comparison between the pre NACT and post two cycles NACT scan is shown in Table 2. Clinically, all 17 patients were classified as responders (8 CR, 9 PR). Among the 8 CR, 6 were true positives and 2 were false positives. Among the 9 PR, 8 were true positives and 1 was false positive.

DISCUSSION
Contrast enhanced CT is the most commonly used modality for the assessment of primary disease and lymph node involvement. In our study too, CECT accurately delineated the site of the primary tumor and lymph node involvement. CECT was, however, not able to detect distant metastasis as it was confined to the site of the primary disease. Also, in recent years, MRI appears to be a more useful modality for the staging of NB and for visualization of anatomical details of the primary tumor, including relationships with the blood vessels. Sixty percent of patients of NB have metastases in cortical bone, bone marrow, lymph nodes and liver. Metastasis to the lung or brain, though rare, is also seen. Forty-one percent of patients in our study had distant metastasis at the time of initial presentation which led to upgradation of the disease stage. These lesions would have been missed had whole body imaging not been performed. Most NB concentrate MIBG and is used routinely for the initial staging of the disease, evaluation of response to treatment, as well as the detection of recurrence. In 5-7% of cases, however, MIBG scintigraphy is negative at presentation. MIBG scintigraphy has high sensitivity (93%) and specificity (100%) for the diagnosis of NB. In the present study, out of 12 patients who underwent MIBG scintigraphy, 11 (92%) showed uptake in the primary tumor. False negative results are usually seen due to pharmacological interference, differentiation and maturation of tumor cells and due to acquisition parameters such as low count rate and resolution constraints. There was no history of drug intake in this one patient in our study. The reason for non-concentration of MIBG in this patient then being a combination of degree of differentiation and resolution constraints. MIBG scintigraphy was, however, not able to delineate regional lymph nodes separate from the primary tumor due to lack of anatomical details. Addition of SPECT and CT to MIBG scintigraphy can increase the accuracy of both methods. False positives can result due to misinterpretation of physiological uptake and can be overcome by serial imaging over time an also by the addition of SPECT/CT. In patients where MIBG uptake is not seen, PET using $^{18}$F-FDG, $^{18}$F-dihydroxyphenylalanine (DOPA), or $^{68}$Ga-(DOTA-D-Phe1]-Tyr3]-octreotide(DOTATOC) might be indicated. Skeletal scintigraphy has long been used as the procedure of choice to assess bony involvement in diseases of diverse aetiology including NB. There seems to be a complementary role for MIBG and MDP for evaluation of bone metastasis in patients with NB. Three out of 12 patients in our study showed presence of skeletal metastasis on...
bone scan. All lesions were concordant on bone scan and MIBG scan. A study by Bouvier et al, comparing MIBG and bone scans, reported similar sensitivities (87.5%) for detection of skeletal metastasis. However, the specificity of MIBG was much higher (100%) as compared to bone scans (81%).

PET-CT in recent years has emerged as an effective functional imaging modality for solid tumors such as NB. Earlier studies have shown that NB and their metastasis including those that did not absorb MIBG intensely accumulated FDG. PET was also found to be equal or superior to MIBG for identifying NB in soft tissue and extracranial skeletal structures, for revealing small lesions and for delineating the extent and localizing sites of disease. PET and MIBG scans showed more skeletal lesions than bone scans, apart from those in the cranial vault. In our study, all patients showed FDG uptake in the primary tumor, including the one which did not concentrate MIBG. However, due to the high FDG uptake in the primary tumor, regional lymph nodes
could not be delineated separately. PET-CT detected additional skeletal lesions due to its better resolution capacity. Metastasis to the marrow, lung and meninges were missed on MIBG and bone scan and detected by PET-CT. Hence, PET-CT was beneficial in staging of NB as it has the added advantage of detecting the primary tumor, skeletal and soft tissue metastasis in a single investigation. An earlier study on a larger number of patients comparing the diagnostic utility of $^{123}$I-MIBG scintigraphy and $^{18}$F-FDG PET in NB, has shown that $^{18}$F-FDG PET was superior in depicting stage 1 and 2 NB. PET-CT was also useful in patients with tumors that either did not accumulate or poorly accumulated MIBG.\cite{32}

Early chemotherapy response evaluation in pediatric tumors has been widely studied in lymphomas.\cite{33,34} As per our knowledge, there is no study, as of now, assessing early response to NACT in NB patients. We assessed the response to NACT after two cycles and observed that 65% of our patients showed improvement in both CT and PET-CT. All these patients had high uptake on the baseline scan. Histopathology was available in nine

Figure 5: Transaxial CT, PET, PET-CT and maximum intensity projection images (L-R) images of a patient with NB. Baseline scan (upper row) shows a right suprarenal mass with intense uptake. Scan done post two cycles of NACT (lower row) shows no significant reduction in the size of the mass whereas there is a reduction in the FDG uptake. These finding are suggestive treatment response on PET-CT but no significant response on CT.

Figure 6: Transaxial CT, PET and PET-CT images (L-R) images of a patient with NB. Baseline scan (upper row) shows presence of meningeal metastasis. Scan done post two cycles of NACT (lower row) shows significant reduction in the FDG uptake. These finding are suggestive significant treatment response on PET-CT but partial significant response on CT.
patients and revealed poorly differentiated tumor in five patients, undifferentiated in two patients and ganglioneuroblastoma with neuroblastic elements in another two patients. One patient showed discordant findings on PET and CT. CR of FDG uptake with no change in size was seen in this patient. This was because PET-CT being a metabolic imaging modality detected changes in the radiotracer uptake before structural alterations could take place. Five patients showed no response on PET as well as CT. Four out of these five patients had low baseline FDG uptake. All four patients are disease free on follow-up thus indicating lower efficacy of PET-CT for assessment of chemotherapy response in patients with initial low FDG uptake. Histopathology available in two of these patients with lower baseline uptake (patients 2 and 8) revealed ganglioneuroblastoma with neuroblastic elements. One patient had high baseline FDG uptake. PET-CT done post two cycles of NACT in this patient showed progression of the disease process.

In our study, seven out of 17 patients had symptomatic and PET findings mismatch. Out of the seven patients not showing any response on PET, three showed CR and four PR clinically. During follow-up, one of them died and the remaining six continue to be disease-free. Three patients expired during follow-up. In two of these patients, the primary tumor had shown good response to NACT clinically, on CT and PET-CT. One had shown response clinically; however, there was no response on CT/ PET-CT. Two of these patients had distant metastases at the time of diagnosis, thus indicating a worse prognosis irrespective of the FDG uptake and response in the primary tumor. The study, however, has its own limitations. The total number of cases is small. The follow-up period is also short in some patients so the real prognostic meaning of the degree of FDG uptake and long-term response to induction chemotherapy cannot be assessed. As non-contrast CT was used in PET-CT, characterization of structures was inferior and hence a separate contrast CT was required most of the times.

CONCLUSION

PET-CT has potential in the initial staging of NB. PET-CT also appears to be a good modality for response assessment in patients with moderate and high FDG uptake on the baseline scan. However, no significant beneficial effect was seen in patients with low baseline FDG uptake.

ACKNOWLEDGMENT

We sincerely thank Council of Scientific and Industrial Research (CSIR), New Delhi, India for funding.

REFERENCES

1. Raeman GH, Bleyer WA. Infants and adolescents with cancer: Special considerations. In: Pizzo PA, Poplak DG, editors. Principles and practice of pediatric oncology, 5th ed. Philadelphia Lippincott-Raven; 2003. p. 452-75.
2. Bouvaros A, Kirks DR, Grossman H. Imaging of neuroblastoma: An overview. Pediatr Radiol 1986;16:89-106.
3. Brodeur GM, Seeger RC, Barret A, Berthold F, Castleberry RP, D’Angio G, et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-81.
4. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castleberry RP, et al. Revisions in the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
5. Zagar I, Han R, Mitrovic S. Meta-[131I]iodobenzylguanidine in the scintigraphic evaluation of neural crest tumors. Q J Nucl Med 1995;39:13-6.
6. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679-88.
7. Kashner BH, Yeung HW, Larson SM, Kramer K, Cheung NK. Extending positron emission tomography scan utility to high-risk neuroblastoma: Fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001;19:3397-405.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
9. Therasse P, Arbuégue SG, Eisenhauer EA, Wanders J, Kaplan RS, Ruhenstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
10. Eisenhauer EA, Therasse P, Bogarts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
11. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L. Monitoring of early response to chemotherapy in stage II and III breast cancer by 18F-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24:5366-72.
12. Stark DD, Moss AA, Brash RC, Stark DD, Moss AA, Brash RC, et al. Neuroblastoma: diagnostic imaging and staging. Radiology 1983;148:101-5.
13. Kashner BH. Neuroblastoma: A disease requiring a multitude of imaging studies. J Nucl Med 2004;45:1172-88.
14. Siegel MJ, Ishwaran H, Fletcher BD, Meyer JS, Hoffer FA, Jaramillo D, et al. Staging of neuroblastoma at imaging: Report of the radiology diagnostic oncology group. Radiology 2002;223:168-75.
15. Pfluger T, Schmied C, Pern P, Leinsinger G, Vollmar C, Dresel S, et al. Integrated imaging using MRI and 123I-metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma. AJR Am J Roentgenol 2003;181:1115-24.
16. DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9.
17. Cowie F, Corbett R, Pinkerton CR. Lung involvement in neuroblastoma: Incidence and characteristics. Med Pediatr Oncol 1997;28:429-32.
18. Matthay KK, Brisse H, Couanet D, Couturier J, Benard J, Mosseri V, et al. Central nervous system metastases in neuroblastoma: Radiologic, clinical, and biologic features in 25 patients. Cancer 2003;98:155-65.
19. Grainger RG, Allison DJ. Diagnostic radiology: A textbook of medical imaging, 4th ed. London: Churchill Livingstone; 2001:1483-6.
20. Porson AS, Krug B, Tuerlinckx D. Additional value of 1-123 MIBG SPECT in neuroblastoma. Clin Nucl Med 2005;30:100-1.
21. Freitas JE. Adrenal cortical and medullary imaging. Semin Nucl Med 1995;25:235-50.
22. Boubaker A, Delaloye AB. MIBG scintigraphy for the diagnosis and follow up of children with neuroblastoma. Q J Nucl Med Mol Imag 2006;52:388-402.
23. Hadji-Djilani NL, Lebrat NE, Delaloye AB, Laurini R, Beck D. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med 1995;22:322-9.
24. Bocher M, Balan A, Krause Y, Shrem Y, Lonn A, Wilk M, et al. Gamma camera–mounted anatomical X-ray tomography: Technology, system characteristics and first images. Eur J Nucl Med 2000;27:19-27.
25. Ilias I, Paek K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 2005;37:717-22.
26. Scanga DR, Martin WN, Delbeye D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 2004;29:86-90.
27. Bhogate BM, Samuel AM, Ramanathan P. Bone scans in neuroblastoma. Indian J Cancer 1993;30:5-9.
28. Sautter-Bihl ML, Bihl H, Heinze HG. The place of 99mTc-MDP skeletal scintigraphy in neuroblastoma. Is a new assessment necessary? Nuklearmedizin 1991;30:7-12.
29. Turba E, Fagioli G, Mancini AF, Rosito P, Galli A, Alvisi P. Evaluation of stage 4 neuroblastoma patients by means of MIBG and 99mTc-MDP scintigraphy. J Nucl Biol Med 1993;37:107-14.
30. Bouvier JF, Philip T, Chauvot P, Brunat Mentigny M, Ducrêmet F, Maïssi N, et al. Pitfalls and solutions in neuroblastoma diagnosis using radioiodine MIBG: our experience about 50 cases. Prog Clin Biol Res 1988;271:707-20.
31. Shulkin BL, Mitchell DS, Ungar DR, Prakash D, Dole MG, Castle VP, et al. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies. Radiology 1995;194:495-500.
32. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL, 123I MIBG Scintigraphy and 18F-FDG PET in neuroblatoma. J Nucl Med 2009;50:1237-43.
33. Riad R, Omar W, Korb M, Hafez M, Sidhom I, Zamzam M, et al. Role of PET-CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging 2010;37:319-29.
34. Furth C, Steffen IG, Amthauer H, Ruf J, Misch D, Schönberger S, et al. Early and late therapy response assessment with 18F-fluorodeoxyglucose positron emission tomography in pediatric Hodgkins lymphoma: Analysis of a prospective multicenter trial. J Clin Oncol 2009;27:4385-91.

**Source of Support:** Council of Scientific and Industrial Research (CSIR), New Delhi, India, **Conflict of Interest:** None declared.